CPHI Pharma Awards 2025 finalists announced
Winners of this year's awards will be revealed during the opening of CPHI Frankfurt 2025.
List view / Grid view
Winners of this year's awards will be revealed during the opening of CPHI Frankfurt 2025.
The deal with the US biopharma could help address metabolic dysfunction-associated steatohepatitis, one of the most prevalent comorbidities of obesity.
Partners with Vela for transatlantic medicine transportation using its cargo trimaran.
The German pharma company will create over 200 jobs at its new Blarney site in Cork.
The new $5 billion manufacturing site is set to become the company’s first integrated facility for API and drug product manufacturing.
The company’s investment strategy will also encompass AI, digital technology and supply chain infrastructure.
Expanding its collaboration with the US biotech will add novel molecular glue degrader-based medicines to the pharma company’s pipeline.
Prague-based pharma company is acquired by GTCR from Advent.
He takes over at the CRO from Peter Benton and brings experience from GHO Capital, Syneos Health and INC Research.
The ICH Assembly’s decision supports progress in promoting international standards for safety assessment of medicines.
Biotech and research investments from Lilly and AstraZeneca also put on hold as pricing row rumbles on.
The novel approach could enhance quality testing applications in pharmaceutical manufacturing.
The company’s CEO says the shift will help prioritise investment into obesity and diabetes, the company’s leading therapy areas.
The innovation is set to change how eligible bladder cancer patients in the US are treated who are unresponsive to traditional therapy.
The October event at Messe Frankfurt is expected to welcome more than 63,000 pharmaceutical professionals.